News Sentiment

CLNN sentiment intelligence

Clene Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 39 relevant articles
Exchange NASDAQ United States
Sector Consumer Defensive Market context
Industry Packaged Foods Read-through group
Latest close 6.27 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+2.8% over one week, +7.4% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Enterprise value to EBIT forward of Clene Inc. – NASDAQ:CLNN

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 2.8% Price confirming higher
Trend fit Trend active 7.4% over four weeks
Fair value -5.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 26
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 8
Quartr 8
TradingKey 7
Stock Titan 7
Market source 3
Intellectia AI 1
NeurologyLive 1
MSN 1

Event Lens

What the news is about

Classified themes
Market update 18
Earnings 11
Regulatory and legal 5
Deals and strategy 2
Analyst action 1
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 39
TradingView Direct company coverage

Enterprise value to EBIT forward of Clene Inc. – NASDAQ:CLNN

This article provides financial data for Clene Inc. (NASDAQ:CLNN), specifically focusing on its enterprise value to EBIT forward. It appears to be a financial snapshot from TradingView, offering an overview of the company's financial metrics. The original content is primarily nav

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 00:11
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Clene Inc – FWB:84C0

This article focuses on the enterprise value to revenue forward of Clene Inc (FWB:84C0) based in the Health Technology sector. It presents financial overview, news, documents, community forecasts, and seasonal data for the company on the Frankfurt Stock Exchange. The webpage is p

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 01:39
Source
TradingView
Quartr Direct company coverage

Clene (CLNN) Q2 Virtual Investor Summit Event earnings summary

Clene (CLNN) held a Q2 Virtual Investor Summit focusing on its strategic commitment to neurodegenerative diseases, particularly ALS, MS, and Parkinson's, using its catalytic nanotherapeutic, Au8. The company reported on clinical trials for ALS and MS, noting that while primary en

Tone
Positive 72/100
Event
Earnings
Published
10 Jul 2026 16:40
Source
Quartr
TradingView Direct company coverage

Enterprise value to EBIT forward of Clene Inc – FWB:84C0

This page provides financial data for Clene Inc (FWB:84C0) on the Frankfurt Stock Exchange, specifically focusing on its Enterprise Value to EBIT forward. It indicates that the market is currently closed with no trades. The content primarily lists various general TradingView feat

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 23:10
Source
TradingView
Quartr Direct company coverage

Clene (CLNN) Study Update Summary

Clene (CLNN) has provided an update on its study findings for CNM-Au8, focusing on its potential as a treatment for ALS. The FDA has indicated willingness to consider neurofilament light (NfL) as a surrogate endpoint for accelerated approval, provided biomarker changes predict cl

Tone
Positive 71/100
Event
Regulatory and legal
Published
09 Jul 2026 03:05
Source
Quartr
Quartr Direct company coverage

Clene (CLNN) Proxy filing Summary

Clene (CLNN) has released a proxy filing summary detailing the agenda for its annual meeting on May 21, 2026. Shareholders will vote on the election of three Class III directors, ratification of Deloitte & Touche LLP as the independent accounting firm, advisory approval of compen

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 02:39
Source
Quartr
Quartr Direct company coverage

Clene (CLNN) Registration Filing Summary

This article summarizes Clene's (CLNN) registration filing, outlining its business model as a clinical-stage pharmaceutical company developing nanotechnology therapeutics for CNS disorders. It details the company's financial performance, including significant operating losses and

Tone
Negative 36/100
Event
Market update
Published
08 Jul 2026 15:11
Source
Quartr
Quartr Direct company coverage

Clene (CLNN) Emerging Growth Conference 92 Summary

Clene (CLNN) presented a summary of its Emerging Growth Conference 92, detailing regulatory progress for its ALS treatment. The company received positive FDA post-meeting minutes, indicating data may support an NDA submission, with neurofilament light reduction being pursued as a

Tone
Positive 71/100
Event
Regulatory and legal
Published
08 Jul 2026 13:41
Source
Quartr
Quartr Direct company coverage

Clene (CLNN) Q4 2025 earnings summary

Clene (CLNN) held an in-person FDA Type C meeting for CNM-Au8 data by the end of Q1 2026, with plans to file an NDA for CNM-Au8 in ALS under accelerated approval by the end of June 2026. The company also completed an oversubscribed $28M direct offering, extending its cash runway.

Tone
Positive 65/100
Event
Earnings
Published
08 Jul 2026 13:41
Source
Quartr
Quartr Direct company coverage

Clene (CLNN) Emerging Growth Virtual Conference Summary

Clene (CLNN) presented a summary of its Emerging Growth Virtual Conference, highlighting its focus on therapies for neurodegenerative diseases like ALS and MS, with lead asset CNM-Au8. The company reported statistically significant reductions in biomarkers and survival benefits i

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 02:11
Source
Quartr
TradingView Direct company coverage

Enterprise value to EBITDA forward of Clene Inc. – NASDAQ:CLNN

The article focuses on the enterprise value to EBITDA forward metric for Clene Inc. (NASDAQ: CLNN). It presents this financial data point within the context of TradingView's platform, indicating its relevance for investors and financial analysts. The article itself is very brief,

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 13:09
Source
TradingView
TradingView Direct company coverage

Clene Inc Actuals & Estimates (NASDAQ:CLNN)

This article provides an overview of Clene Inc. (NASDAQ: CLNN) stock, including its current price, performance trends, analyst forecasts, and financial data. It covers historical price movements, market capitalization, volatility, and upcoming earnings reports, along with past ea

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Clene Inc. – BOATS:CLNN

This article provides financial information for Clene Inc. (CLNN) on the Blue Ocean Alternative Trade System (BOATS). It specifically focuses on the company's "Price to earnings forward" metric. The content highlights the period, value, and change information for this financial i

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 00:42
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Clene Inc. – BOATS:CLNN

This article provides the enterprise value to EBIT forward for Clene Inc. (CLNN) as traded on the Blue Ocean Alternative Trade System (BOATS). It presents financial data with disclaimers regarding its sourcing from ICE Data Services and FactSet Research Systems Inc., and intellec

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 17:40
Source
TradingView
TradingView Direct company coverage

CLNN Forecast — Price Target — Prediction for 2027

The article provides a forecast and price target for Clene Inc. (CLNN) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical high and low prices, market capitalization, volatility, and details on past and upcoming earnings and revenu

Tone
Positive 61/100
Event
Analyst action
Published
24 Jun 2026 13:11
Source
TradingView
TradingKey Direct company coverage

Clene Inc. (CLNN) Financial Health: Profitability & Balance Sheet Analysis

Clene Inc. (CLNN) has a weak financial status with a current score of 5.65, ranking low in the Biotechnology & Medical Research industry. The company reported a significant year-over-year decrease in revenue by 81.48% and a net profit decrease of 977.36% in its latest quarterly r

Tone
Negative 18/100
Event
Earnings
Published
23 Jun 2026 19:10
Source
TradingKey
TradingKey Direct company coverage

Clene Inc. (CLNNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Clene Inc. (CLNNW), focusing on indicators and moving averages. It details the current status of various technical indicators like MACD, RSI, and STOCH, along with an overview of moving averages from MA5 to MA200. The analysis indicat

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 07:49
Source
TradingKey
TradingKey Direct company coverage

Clene Inc. (CLNNW) Institutional Confidence

This article provides an overview of Clene Inc.'s (CLNNW) institutional confidence, focusing on shareholder activity. It shows changes in shares held by various institutional investors, with several firms significantly reducing or eliminating their holdings. The report highlights

Tone
Neutral 50/100
Event
Market update
Published
19 Jun 2026 00:49
Source
TradingKey
TradingKey Direct company coverage

Clene Inc. (CLNN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Clene Inc. (CLNN) currently has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $30.00 for CLNN, with an expected revenue of $73.50K for the next quarter. Most analysts recommend a

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 12:40
Source
TradingKey
TradingKey Direct company coverage

Clene Inc. (CLNNW) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Clene Inc. (CLNNW) focusing on its dividend and stock split history. It indicates that the company has distributed $0.00 in dividends over the past five years and has no recorded stock split data. The page also presents basic stock information

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 08:40
Source
TradingKey
TradingKey Direct company coverage

Clene Inc. (CLNN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article for Clene Inc. (CLNN) on TradingKey discusses the company's revenue breakdown, including business segments and regional contributions. However, it notes that relevant data for these categories have not been disclosed by the company yet. The article provides current s

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 17:39
Source
TradingKey
TradingKey Direct company coverage

Clene Inc. (CLNN) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Clene Inc.'s (CLNN) dividend history and stock split events. It states that Clene Inc. has distributed no dividends over the past five years. The article also lists upcoming stock split events, all identified as "Merger 20→1" on July 9, 2024.

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Jun 2026 17:39
Source
TradingKey
Stock Titan Direct company coverage

Clene (CLNN) CEO receives 65,000 stock options at $5.53 exercise price

Clene Inc. President and CEO Robert Dee Etherington was granted 65,000 stock options with an exercise price of $5.53 per share, expiring on June 10, 2036. The options will vest 25% on June 11, 2027, with the remainder vesting in 36 equal monthly installments thereafter. This gran

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 18:39
Source
Stock Titan
Stock Titan Direct company coverage

Clene (CLNN) Chief Science Officer receives 45,000-share stock option grant

Clene Inc.'s Chief Science Officer, Mark Mortenson, was granted stock options for 45,000 shares with an exercise price of $5.53 per share, expiring in 2036. This compensation-related award vests 25% on June 11, 2027, with the remainder vesting in 36 equal monthly installments the

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 18:39
Source
Stock Titan
Stock Titan Direct company coverage

Clene (CLNN) grants CFO 15,000 stock options at $5.53 strike

Clene Inc. (CLNN) has granted its Chief Financial Officer, Morgan R. Brown, 15,000 stock options with an exercise price of $5.53 per share, expiring on June 10, 2036. The options will vest 25% on June 11, 2027, with the remaining 75% vesting in 36 equal monthly installments there

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 18:39
Source
Stock Titan
Intellectia AI Direct company coverage

CLNN Technical Analysis & Stock Price Forecast

The article provides a technical analysis and stock price forecast for Clene Inc (CLNN), indicating a Neutral overall consensus based on various technical indicators as of May 29, 2026. It details momentum indicators like RSI and MACD, support and resistance levels, and different

Tone
Neutral 50/100
Event
Guidance
Published
30 May 2026 05:09
Source
Intellectia AI
NeurologyLive Direct company coverage

Clene Moves Toward Accelerated Approval NDA Filing for CNM-Au8 in ALS

Clene Nanoscience plans to submit an NDA for accelerated FDA approval of its investigational agent CNM-Au8 for ALS treatment, primarily based on neurofilament light (NfL) biomarker data and phase 2 studies. The FDA indicated that the available dataset might support review under a

Tone
Positive 67/100
Event
Regulatory and legal
Published
23 May 2026 18:41
Source
NeurologyLive
MSN Direct company coverage

CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment

CLNN stock saw an 8% increase today following an FDA update regarding Clene's investigational ALS treatment, CNM-Au8. The FDA granted a Fast Track designation for the drug, indicating it addresses an unmet medical need for a serious condition. This designation will expedite the r

Tone
Positive 70/100
Event
Regulatory and legal
Published
23 May 2026 15:38
Source
MSN